Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Ibrutinib,IBR12020US,2020,USA,MDV,350,72,35,65,27.5,42,85,5,15,30,40,15,55,25,15,5,20,35,45,18,8,5,12,7,10,25,30,R-CHOP,Hyper-CVAD,Rituximab,Bendamustine,2,1,1,20,30,40,15,45,40,60,2
Ibrutinib,IBR22021EU,2021,Germany,Claim Database,420,75,40,60,28.1,38,78,7,12,28,45,15,50,30,15,5,18,32,50,20,10,6,14,8,8,22,28,R-CVP,DHAP,Rituximab,Chlorambucil,3,2,1,22,32,42,10,50,40,65,3
Ibrutinib,IBR32022CA,2022,Canada,MDV,280,70,38,62,26.8,40,82,6,14,29,42,15,52,28,16,4,19,33,48,19,9,5,13,7,9,23,29,R-CHOP,Hyper-CVAD,Rituximab,Bendamustine,2,1,1,21,31,41,12,48,40,62,2.5
Ibrutinib,IBR42023UK,2023,UK,Claim Database,380,73,37,63,27.2,39,80,5,13,27,44,16,51,29,17,3,17,31,52,21,11,7,15,9,7,21,27,R-CVP,DHAP,Rituximab,Chlorambucil,3,2,1,23,33,43,9,51,40,67,3.5
